CSIMarket
 
Moonlake Immunotherapeutics  (NASDAQ: MLTX)
Other Ticker:  
 
 
Price: $45.0600 $-2.05 -4.352%
Day's High: $48.54 Week Perf: 3.23 %
Day's Low: $ 44.87 30 Day Perf: -10.26 %
Volume (M): 286 52 Wk High: $ 64.98
Volume (M$): $ 12,865 52 Wk Avg: $47.29
Open: $47.08 52 Wk Low: $37.55



 Market Capitalization (Millions $) 2,834
 Shares Outstanding (Millions) 63
 Employees 23
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) 57
 Capital Exp. (TTM) (Millions $) 1

Moonlake Immunotherapeutics
Moonlake Immunotherapeutics is a biotechnology company that focuses on developing innovative immunotherapeutic therapies for cancer. They are a rising star in the biotech industry and have gained global attention for their groundbreaking research.

The company is based in San Francisco, California, and was founded in 2019 by a team of seasoned scientists and business professionals. The team at Moonlake is driven by a shared vision to improve cancer treatment outcomes by harnessing the power of the immune system.

Moonlake's proprietary technology platform is built on a deep understanding of the complex interaction between the immune system and cancer cells. The platform is designed to identify and target specific cancer cells, while leaving healthy cells untouched. This approach minimizes harmful side effects and allows for higher treatment effectiveness. The technology is based on four pillars: T cell activation, immune system modulation, targeted cell death, and antigen targeting.

Moonlake's lead development program is focused on a novel technology called the Multi-Mode Intracellular Targeting (MMIT) Platform. This technology is designed to specifically target and destroy cancer cells, while leaving normal cells unharmed. It works by delivering a unique combination of signaling molecules within cancer cells, leading to apoptosis, or programmed cell death. The MMIT technology has been shown to be effective in a broad range of cancer types.

In addition to the MMIT platform, Moonlake is also pursuing other innovative approaches to treating cancer. These include CAR-T cell therapy, antibody-drug conjugates, and cancer vaccines. The company's goal is to develop a diverse portfolio of novel therapies that can be used in combination with each other to improve patient outcomes.

In summary, Moonlake Immunotherapeutics is a cutting-edge biotechnology company that is pioneering the development of innovative immunotherapeutic cancer treatments. Their unique technology platform and diverse portfolio of therapies have the potential to revolutionize cancer treatment and improve patient outcomes.


   Company Address: Dorfstrasse 29 Zug 6300
   Company Phone Number: 415108022   Stock Exchange / Ticker: NASDAQ MLTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.38% 
BMY   -7.48%    
JNJ   -0.57%    
LLY        4.74% 
MRK   -3.6%    
PFE   -0.77%    
• View Complete Report
   



Announcement

In a significant stride towards addressing active psoriatic arthritis, MoonLake Immunotherapeutics has init...

Published Wed, Nov 13 2024 1:01 PM UTC

MoonLake Immunotherapeutics Advances Phase 3 Trial Amidst Revenue Challenges: Unyielding Focus on Nanobody Sonelokimab for Psoriatic Arthritis In a significant stride towards addressing active psoriatic arthritis, MoonLake Immunotherapeutics has initiated its Phase 3 IZAR program for Nanobody sonelokimab. This therapeutic agent is designed to alleviate symptoms of a conditio...

Announcement

Unlocking Potential MoonLake Immunotherapeutics Poised for Growth Through Regulatory Milestones and Capital Markets U...

Published Mon, Sep 9 2024 11:00 AM UTC

MoonLake Immunotherapeutics: Bridging Innovation and Capital Markets in Psoriatic Arthritis Treatment In an era where biotechnology and pharmaceuticals are at the forefront of healthcare innovation, MoonLake Immunotherapeutics has become a notable player in the therapeutic landscape, particularly with its promising nanobody, sonelokimab, designed to treat psoriatic arthritis...

Announcement

MoonLake Immunotherapeutics Receives Positive Regulatory Feedback for Sonelokimab Phase 3 Program in Psoriatic Arthri...

Published Mon, Jun 10 2024 12:00 PM UTC

MoonLake Immunotherapeutics, a biopharmaceutical company focused on the development of innovative immunotherapies, recently announced positive regulatory feedback from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the Phase 3 program for their nanobody, sonelokimab, in the treatment of Psoriatic Arthritis. This news marks ...

Moonlake Immunotherapeutics

Moonlake Immunotherapeutics Reports Operating Deficit of $-19.820489 Million, Sparking Concern Among Shareholders



Moonlake Immunotherapeutics, a major player in the pharmaceutical preparations industry, recently reported a temporary setback in its earnings for the fiscal period from January to March 2024. A significant operating deficit and net loss were observed, causing concern among shareholders. However, it is important to analyze these results in the context of the overall market sentiment, growth potential, and long-term prospects.
Overcoming Temporary Challenges:
While the operating deficit of $-19.820489 million may have caught many shareholders off-guard, it is crucial to remember that the current developing period of the corporation indicates the potential for additional revenue sources in the near future. This reassurance is attributed to the expectations that Moonlake Immunotherapeutics' stakeholders hold, which further fuels their confidence in the firm.

Moonlake Immunotherapeutics

Financial Turnaround: Moonlake Immunotherapeutics Reports Significant Decrease in Operating Loss and Diminishing Returns

Moonlake Immunotherapeutics is a small pharmaceutical company that has been making headlines in the Major Pharmaceutical Preparations sector with its latest financial performance. The company has shown significant improvement in its operating loss, decreasing from $-29.927 million in the fourth quarter of 2022 to $-15.028897 million in the same period of 2023. This is a positive sign for Moonlake Immunotherapeutics as it demonstrates a strong commitment to cost-effectiveness and financial stability.
One of the key indicators of Moonlake Immunotherapeutics' potential for growth is the decrease in diminishing returns, which have declined to $-7.887 million in the fourth quarter of 2023 from $-29.644 million in the previous year. This trend suggests that the company is on the right path to becoming a major player in the Healthcare sector. Additionally, the increase in accounts receivable is a promising sign of rising demand for Moonlake Immunotherapeutics' products and services.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com